181210-18-4

Basic information

• Product Name: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine
• Synonyms: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine
• CAS NO: 181210-18-4
• Molecular Formula: C₁₉H₂₄N₂O₂S
• Molecular Weight: 344.47106
• Mol File: 181210-18-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 472.597 °C at 760 mmHg
• Flash Point: 239.619 °C
• Appearance: /
• Density: 1.23
• CAS DataBase Reference: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine(181210-18-4)
• EPA Substance Registry System: 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine(181210-18-4)

Safety Data

• Hazardous Substances Data: 181210-18-4(Hazardous Substances Data)

Usage

General Description

2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine is a chemical compound with a complex molecular structure. It contains a benzazepine backbone with a sulfonyl group and a methylphenyl substituent. The presence of tetrahydro and dimethyl groups suggests that it is a cyclic amine with methyl substituents on the nitrogen atoms. 2,3,4,5-Tetrahydro-N,N-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-1-benzazepin-5-amine may have potential pharmaceutical or biological applications due to its unique structure and properties. However, further research and testing would be necessary to fully understand its potential uses and effects.

Upstream product

• 50-00-0 formaldehyd 
• 50998-74-8 methyl N-tosylanthranilate 
• 24310-36-9 1-tosyl-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one 
• 134-20-3 2-carbomethoxyaniline 
• 98-59-9 p-toluenesulfonyl chloride 
• 125715-24-4 1-(2-nitrophenyl)but-3-en-1-ol 
• 881417-01-2 2-[1-tert-butyldimethylsilyloxy-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-06-7 2-[1-tert-butoxycarbonylamino-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-07-8 2-[1-(N-methyl-tert-butoxycarbonylamino)-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-08-9 2-[1-(N-methyl-tert-butoxycarbonylamino)-4-(tetrahydropyran-2-yloxy)butyl]aniline 
• 881417-05-6 2-[1-azido-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-02-3 2-[1-hydroxy-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-00-1 2-(1-tert-butyldimethylsilyloxy-4-hydroxybutyl)nitrobenzene 
• 881416-99-5 2-(1-tert-butyldimethylsilylbut-3-enyl)nitrobenzene 

Downstream Products

• 165309-37-5 5-dimethylamino-1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-benzoazepine 
• 181210-00-4 N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-2-nitro-benzamide 
• 181210-02-6 2-Amino-N-[4-(5-dimethylamino-2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-benzamide 
• 137975-06-5 mozavaptan 
• 165309-36-4 5-dimethylamino-1-(4-nitro-benzoyl)-2,3,4,5-tetrahydro-1H-benzoazepine 
• 155061-62-4 5-dimethylamino-2,3,4,5-tetrahydro-1H-benzoazepine 

Relevant articles and documents

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure-affinity and structure-efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.

Orally active, nonpeptide vasopressin V2 receptor antagonists: A novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds

This paper describes a novel series of nonpeptide vasopressin V2 receptor antagonists. It has been demonstrated that the 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-benzazepines and 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-1,5-benzodiazepines show a high affinity for V2 (and V(1a)) receptors. Among the 1-[4-(benzoylamino)benzoyl]-2,3,4,5- 1H-benzazepine series, compounds with an alkylamino group on the benzazepine ring have been shown to have oral activity. A lipophilic group at the ortho position on the terminal benzoyl ring is important for both high V2 receptor affinity and oral activity. On the basis of these favorable properties, clinical testing of 31b has begun for use as an oral and iv aquaretic agent.